Award
National Cancer Institute 11362040
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
Recipient
Roswell Park Cancer Institute Corp
Award Amount
$1,750,151.00
Ceiling
$1,750,151.00
Awarded
July 27, 2026
Identifier
11362040
Research grant awarded to study racial disparities in immune checkpoint inhibitor treatment outcomes among cancer survivors in a community oncology setting.
Description
A research grant opportunity from the NIH/NCI for a cohort study on immune checkpoint inhibitors and racial disparities. The project aims to understand racial differences in treatment outcomes and adverse events among cancer survivors.